{"transactions":[{"id":350903,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-03-23T20:14:26.000Z","date":"2023-03-17","kind":"purchase","planned":false,"acquired":true,"shares":1811594,"price":2.76,"value":4999999.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities were issued under that certain first amendment dated March 16, 2023 to the Amended and Restated License Agreement dated October 14, 2022 between the Reporting Person and the Issuer, pursuant to which the Issuer agreed to issue to the Reporting Person such number of shares of common stock equivalent to $5.0 million at a per share price equal to the closing price of the Issuer's common stock on the business day when the closing price of the Issuer's common stock on the Nasdaq Global Select Market is at or above $2.46 per share on any day between March 16, 2023 and a date that is within 180 days following October 6, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 17, 2023, the closing price of the Issuer's common stock on the Nasdaq Global Select Market was $2.76 per share."}],"balance_after":5952263,"source":{"system":"sec-edgar","filing":"0000078003-23-000052","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000052/primary_doc.xml","form_type":"4/A","original_submission_date":"2023-03-21"}},{"id":350952,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-03-21T22:07:27.000Z","date":"2023-03-17","kind":"purchase","planned":false,"acquired":true,"shares":1811594,"price":2.76,"value":4999999.44,"ownership":{"direct":true},"balance_after":5952263,"source":{"system":"sec-edgar","filing":"0000078003-23-000050","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000050/primary_doc.xml","form_type":"4"}},{"id":382719,"issuer":{"id":879,"kind":"organization","name":"BioAtla, Inc.","symbol":"BCAB"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2020-12-22T22:58:52.000Z","date":"2020-12-18","kind":"exercise","acquired":false,"shares":2238090,"ownership":{"direct":false,"nature":"See Footnote (2)"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Series D Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Series D Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Series D Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Series D Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer Inc."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2238090},"source":{"system":"sec-edgar","filing":"0000078003-20-000080","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000080/primary_doc.xml","form_type":"4"}},{"id":382718,"issuer":{"id":879,"kind":"organization","name":"BioAtla, Inc.","symbol":"BCAB"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-22T22:58:52.000Z","date":"2020-12-18","kind":"exercise","acquired":true,"shares":2238090,"ownership":{"direct":false,"nature":"See Footnote(2)"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series D Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Series D Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer Inc."}],"balance_after":2238090,"source":{"system":"sec-edgar","filing":"0000078003-20-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000080/primary_doc.xml","form_type":"4"}},{"id":389763,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":2,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":3,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-04T20:25:17.000Z","date":"2020-06-03","kind":"sale","acquired":false,"shares":370000,"price":40.18,"value":14866600.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All of the shares disposed of were sold by Pfizer Inc. (\"Pfizer\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents 2,410,071 shares held of record by Pfizer Ventures (US) LLC, a controlled affiliate of Pfizer, 254,205 shares held of record by Pfizer, and 215,697 shares held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":2879973,"source":{"system":"sec-edgar","filing":"0000078003-20-000038","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000038/primary_doc.xml","form_type":"4"}},{"id":393037,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-16T23:15:07.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":1894444,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pfizer Ventures (US) LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each reporting person disclaims ownership of securities held by each other reporting person, except to the extent of its respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":300752},"source":{"system":"sec-edgar","filing":"0000078003-20-000023","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000023/primary_doc.xml","form_type":"4"}},{"id":393036,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-03-16T23:15:07.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":5470492,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pfizer Ventures (US) LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On March 16, 2020, each share of Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 16, 2020, each share of Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 16, 2020, each share of Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each reporting person disclaims ownership of securities held by each other reporting person, except to the extent of its respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":868467},"source":{"system":"sec-edgar","filing":"0000078003-20-000023","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000023/primary_doc.xml","form_type":"4"}},{"id":393035,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2020-03-16T23:15:07.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":478749,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On March 16, 2020, each share of Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series Seed Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 16, 2020, each share of Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series Seed Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 16, 2020, each share of Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series Seed Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each reporting person disclaims ownership of securities held by each other reporting person, except to the extent of its respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":76003},"source":{"system":"sec-edgar","filing":"0000078003-20-000023","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000023/primary_doc.xml","form_type":"4"}},{"id":393034,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T23:15:07.000Z","date":"2020-03-16","kind":"purchase","acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":false,"nature":"By Pfizer Ventures (US) LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pfizer Ventures (US) LLC purchased 312,500 additional shares of common stock in the Issuer's initial public offering at the initial public offering price of $16.00 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each reporting person disclaims ownership of securities held by each other reporting person, except to the extent of its respective pecuniary interest therein."}],"balance_after":1481719,"source":{"system":"sec-edgar","filing":"0000078003-20-000023","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000023/primary_doc.xml","form_type":"4"}},{"id":393033,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T23:15:07.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":300752,"ownership":{"direct":false,"nature":"By Pfizer Ventures (US) LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each reporting person disclaims ownership of securities held by each other reporting person, except to the extent of its respective pecuniary interest therein."}],"balance_after":1169219,"source":{"system":"sec-edgar","filing":"0000078003-20-000023","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000023/primary_doc.xml","form_type":"4"}},{"id":393032,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T23:15:07.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":868467,"ownership":{"direct":false,"nature":"By Pfizer Ventures (US) LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 16, 2020, each share of Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each reporting person disclaims ownership of securities held by each other reporting person, except to the extent of its respective pecuniary interest therein."}],"balance_after":868467,"source":{"system":"sec-edgar","filing":"0000078003-20-000023","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000023/primary_doc.xml","form_type":"4"}},{"id":393031,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T23:15:07.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":76003,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 16, 2020, each share of Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series Seed Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each reporting person disclaims ownership of securities held by each other reporting person, except to the extent of its respective pecuniary interest therein."}],"balance_after":76003,"source":{"system":"sec-edgar","filing":"0000078003-20-000023","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800320000023/primary_doc.xml","form_type":"4"}},{"id":400180,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2019-09-19T20:19:11.000Z","date":"2019-09-17","kind":"exercise","acquired":false,"shares":3465571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series B Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer (\"PVUS\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series B Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer (\"PVUS\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series B Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer (\"PVUS\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series B Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer (\"PVUS\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":526602},"source":{"system":"sec-edgar","filing":"0000078003-19-000071","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000071/primary_doc.xml","form_type":"4"}},{"id":400179,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2019-09-19T20:19:11.000Z","date":"2019-09-17","kind":"exercise","acquired":false,"shares":20000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each share of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3039051},"source":{"system":"sec-edgar","filing":"0000078003-19-000071","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000071/primary_doc.xml","form_type":"4"}},{"id":400178,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Junior Series A Convertible Preferred Stock","published_at":"2019-09-19T20:19:11.000Z","date":"2019-09-17","kind":"exercise","acquired":false,"shares":6437500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Junior Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Junior Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Inc. (\"Pfizer\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Junior Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Junior Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Inc. (\"Pfizer\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Junior Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Junior Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Inc. (\"Pfizer\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Junior Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Junior Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Inc. (\"Pfizer\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":978194},"source":{"system":"sec-edgar","filing":"0000078003-19-000071","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000071/primary_doc.xml","form_type":"4"}},{"id":400177,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-19T20:19:11.000Z","date":"2019-09-17","kind":"purchase","acquired":true,"shares":50000,"price":18,"value":900000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"PVUS purchased such additional shares of Common Stock in the Issuer's initial public offering at the initial public offering price of $18.00 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein."}],"balance_after":4593847,"source":{"system":"sec-edgar","filing":"0000078003-19-000071","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000071/primary_doc.xml","form_type":"4"}},{"id":400176,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-19T20:19:11.000Z","date":"2019-09-17","kind":"exercise","acquired":true,"shares":526602,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series B Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer (\"PVUS\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series B Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer (\"PVUS\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein."}],"balance_after":4543847,"source":{"system":"sec-edgar","filing":"0000078003-19-000071","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000071/primary_doc.xml","form_type":"4"}},{"id":400175,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-19T20:19:11.000Z","date":"2019-09-17","kind":"exercise","acquired":true,"shares":3039051,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each share of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein."}],"balance_after":4017245,"source":{"system":"sec-edgar","filing":"0000078003-19-000071","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000071/primary_doc.xml","form_type":"4"}},{"id":400174,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-19T20:19:11.000Z","date":"2019-09-17","kind":"exercise","acquired":true,"shares":978194,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of Junior Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Junior Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Inc. (\"Pfizer\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Junior Series A Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 6.5810:1 basis upon the closing of the Issuer's initial public offering for no additional consideration. The Junior Series A Convertible Preferred Stock had no expiration date. Such shares are held of record by Pfizer Inc. (\"Pfizer\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Each Reporting Person disclaims ownership of securities held by the other Reporting Person, except to the extent of its pecuniary interest therein."}],"balance_after":978194,"source":{"system":"sec-edgar","filing":"0000078003-19-000071","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000071/primary_doc.xml","form_type":"4"}},{"id":403255,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":624205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":624205},"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403254,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":215697,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":215697},"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403253,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":2360071,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2360071},"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403252,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"purchase","acquired":true,"shares":50000,"price":17,"value":850000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"PVUS purchased 50,000 additional shares of common stock in the Issuer's initial public offering for consideration of $17.00 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":3249973,"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403251,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":624205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":3199973,"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403250,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":215697,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":2575768,"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}},{"id":403249,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15812,"kind":"organization","name":"Pfizer Strategic Investment Holdings LLC","position":3,"cik":"0001776115","reported_name":"Pfizer Strategic Investment Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-14T11:34:53.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":2360071,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Redeemable Convertible Preferred Common Stock (\"Series A Preferred Stock\"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC (\"PVUS\"), a controlled affiliate of Pfizer Inc. (\"Pfizer\"), and each share of the Series B Redeemable Convertible Preferred Stock (\"Series B Preferred Stock\" and together with the Series A Preferred Stock, the \"Preferred Stock\"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the \"Issuer\") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein."}],"balance_after":2360071,"source":{"system":"sec-edgar","filing":"0000078003-19-000027","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800319000027/primary_doc.xml","form_type":"4"}}]}